The COVID - 19 coronavirus: A look at some of the latest studies

4 minutes

April 19 -- The following is a roundup of some of the latest scientific studies on the new coronavirus and efforts to find treatments and vaccines for COVID -- 19, the illness caused by the virus.

Patients with COVID 19, who have been consistently physically inactive have a significantly higher risk of severe consequences than patients who regularly exercised or met physical activity guidelines before the illness, the researchers found. Among the 48,440 patients in their study, 14.4% were consistently inactive in the two years before their COVID 19 diagnosis, 79.1% had some activity and 6.4% met recommended physical activity guidelines of at least 150 minutes per week consistently. Compared to those who consistently met activity guidelines, people who were consistently inactive were more than twice as likely to die from the virus and to be hospitalized, according to a report published in the British Journal of Sports Medicine. Consistently inactive patients also had worse outcomes than patients who got some exercise without meeting the minimum guideline minimization. It is well known that immune function improves with regular physical activity and those who are regularly active have a lower incidence, intensity of symptoms and death from viral infections, said coauthor Dr. Robert Sallis of the Kaiser Permanente Fontana Medical Center in California. Regular physical activity is associated with improvements in lung capacity and cardio and muscular functioning that may serve to reduce the negative effects of COVID 19 if it is not contracted, he added. How to act like a lawyer?

On Monday, British scientists launched a trial that will study the COVID-19 survivors to the coronavirus in order to re-expose their immune responses and see if they get reinfected. The information from the so-called challenge trial will allow us to design better vaccines and treatments, and also to understand if people are protected after COVID, and how long, said study leader Helen McShane of the University of Oxford. The first phase of the trial will aim to establish the lowest dose of coronavirus needed to start replicating in about 50% of volunteers, while producing few to no symptoms. A second phase will infect different volunteers with this standard dose. Everyone will quarantine for at least 17 days, and anyone who develops symptoms will receive a monoclonal antibody treatment manufactured by Regeneron Pharmaceuticals Inc. Researchers are administering the virus to volunteers who were not previously infected in the UK. These challenge studies will significantly improve our understanding of the dynamics of virus infection and the immune response, as well as provide valuable information to help with the ongoing design of vaccines and the development of antiviral therapies, Lawrence Young, a virologist at Warwick Medical School in the UK, said in a statement. Can you tell me what you think?

People who become critically ill with COVID 19 appear to have lower-than average levels of inflammatory proteins called interferons, and a new study helps explain why low interferon levels would matter. Researchers identified 65 genes that are triggered into action by interferons- including some that inhibit the ability of the virus to assemble cells and others that suppress manufacture of the virus' genetic material or inhibit its ability to reproduce itself- part of the viral replication process. Eight of the interferon-stimulated genes are not only directed against the SARS-CoV-1 virus that caused SARS-19, but also against the SARS-2 virus that was responsible for the SARS outbreak in 2003, the researchers reported in Molecular Cell. The interferon response to SARS-CoV-2 infection relies on a limited subset of genes that govern a diverse set of cellular functions, the researchers said. We wanted to gain a better understanding of the cellular response to SARS-CoV -2, including what drives a weak or strong response to infection, said coauthor Sumit Chanda of Sanford Burnham Prebys in La Jolla, California in a statement. We 've gained new insights into how the virus infects the human cells it invades, but we are still trying to find its Achilles heel. How do you come across the best name for an American oedipal disease?

Open https: 3 c 7 R3 Bl in an external browser for a Reuters graphic on vaccines in development.

  • Comments
Loading comments...